Disclosed is the use of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule and at least one additional therapeutic agent selected from docetaxel, vincristine, and topotecan for the manufacture of a medicament for treating cancer in a subject, wherein the medicament is formulated for administration of an effective amount of the FGFR1 ECD fusion molecule and the at least one additional therapeutic agent to the subject, wherein the FGFR1 ECD fusion molecule comprises an FGFR1 ECD comprising an amino acid sequence selected from SEQ ID NOs: 1 to 4 and a fusion partner, and wherein administration of the FGFR1 ECD fusion molecule and the at least one additional therapeutic agent results in synergistic inhibition of tumour growth in a mouse xenograft model of the cancer, wherein the cancer is small cell lung cancer and the mouse xenograft model comprises DMS 53 cells.
